Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jobbins, J.
Right arrow Articles by Newcombe, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jobbins, J.
Right arrow Articles by Newcombe, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A clinical trial of chlorhexidine oral spray in terminally ill cancer patients

J. Jobbins

South Glamorgan Health Authority

M. Addy

University of Wales College of Medicine, Cardiff

J. Bagg

University of Wales College of Medicine, Cardiff

I. Finlay

Holme Tower Marie Curie Centre, Penarth, Cardiff

K. Parsons

University of Wales College of Medicine, Cardiff

RG Newcombe

University of Wales College of Medicine, Cardiff

One hundred and ninety-seven patients with advanced cancer admitted to Holme Tower Marie Curie Centre, Penarth, Wales entered a double blind, single phase placebo-controlled clinical trial of 0.2% chlorhexidine gluconate mouth spray for the control of oral symptoms. The sprays were administered by nursing staff twice daily for two weeks. A detailed questionnaire was completed and the mouth examined at entry and after one and two weeks of spray usage. Oral rinses and imprint cultures were collected at the same time intervals to monitor the effects of each spray on oral carriage of yeasts, coliforms, Staphylococcus aureus and Streptococcus mutans. The results suggested possible limited activity of a chlorhexidine mouth spray after two weeks of use in decreasing oral yeasts, although the difference from placebo did not reach statistical significance. In addition, both active and placebo sprays provided some patients with relief from oral dryness. Overall there was no evidence for efficacy of a chlorhexidine oral spray in patients with advanced cancer.

Key Words: dental care • neoplasms • oral health • palliative treatment • terminal care

Palliative Medicine, Vol. 6, No. 4, 299-307 (1992)
DOI: 10.1177/026921639200600405
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
M. Sweeney, J. Bagg, W. Baxter, and T. Aitchison
Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients
Palliative Medicine, May 1, 1997; 11(3): 225 - 232.
[Abstract] [PDF]